Canaccord Genuity has initiated coverage on Twist Bioscience Corporation, a US-based synthetic biology company, with a buy rating, according to a research note published this week. The investment bank's analysts highlighted the firm's leadership in DNA synthesis and its potential to capture a growing share of the synthetic biology market, which is increasingly used in pharmaceuticals, agriculture, and data storage.
Twist Bioscience, headquartered in South San Francisco, specialises in manufacturing synthetic DNA for a range of applications, including drug discovery and diagnostics. The buy rating comes as the company continues to expand its customer base and improve its manufacturing efficiency. Canaccord's analysts noted that Twist's proprietary silicon-based platform gives it a cost advantage over competitors.
The move is part of a broader trend of analyst attention on the synthetic biology sector, which has seen significant investment in recent years. For UK investors, this coverage provides a fresh perspective on a fast-growing area of life sciences, though Twist Bioscience is not listed on the London Stock Exchange. Its shares trade on the Nasdaq under the ticker TWST.
Analysts at Canaccord set a price target of $55 per share, representing a potential upside from current levels. They cited the company's strong intellectual property portfolio and partnerships with major pharmaceutical firms as key drivers. However, they also acknowledged risks, including competition from established players and the need for continued capital investment.
For UK equity investors and pension funds with exposure to US markets, the rating underscores the importance of monitoring synthetic biology as a growth theme. While no direct FTSE 100 or FTSE 250 stocks are affected, the sector's performance can influence broader biotech ETFs and investment trusts popular among British savers. The FTSE All-Share Index was little changed on the day, with the FTSE 100 closing at 7,684.50 points, down 0.1 per cent.